News Releases | BioAtla, Inc

Date
5/7/24	BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
5/6/24	BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
4/24/24	BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
3/26/24	BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
3/19/24	BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024
3/7/24	BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting